Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 1998

View Archived Issues

Company Profile: Gryphon Sciences

Xoma: Q3 1998 highlights

Schering-Plough files NDA for next-generation corticosteroid

Virological and pharmacokinetic profile presented for structurally novel NNRTIs from DuPont

Alliance formed by Penwest and Chiroscience to combine isomer and drug delivery technologies

OraVax and Pasteur Merieux Connaught codevelop dengue fever vaccine

Philippines is the first market for lamivudine as anti-HBV agent

Shire to apply drug delivery technologies to Searle product

Novel GM-CSF-containing fusion toxin shows excellent antileukemia activity in mouse model

SomatoKine provides significant benefit in severe burn trial

La Jolla presents promising primate data on new xenotransplantation Toleragen candidate

MAb-tyrosine kinase inhibitor immunoconjugate induces disease remission in ALL patients

Dendritic cell therapies based on Dendreon technology focus of Dendreon-Kirin partnership

FDA approves expanded indication for CytoGam

New U.S. patent provides Cortex exclusivity for Ampakine compounds

Novel anticoagulant serpin described by U.S. academics

AEterna signs CTA with NCI and reports lung cancer pivotal trial protocol details

E.U.-wide marketing approval granted for Muse

Japanese ACAT inhibitor is safe and effective in several animal species

New NK1 antagonists with excellent in vitro and in vivo profile designed at Merck & Co.

P&G submits NDA for antiarrhythmic drug azimilide

Clinical testing of inhaled antihistamine appears warranted in asthma patients

Highly potent anti-HIV betulin derivative acts at a late stage in the viral life cycle

Raloxifene evaluated for one year in established postmenopausal osteoporosis

Celgene acquires EntreMed rights to thalidomide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...